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identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain
whether CSFAD biomarkers outperform imaging biomarkers. Operational recommendations for the
interpretation of ambiguous CSF biomarker results were also provided.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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Dementia, or major neurocognitive disorder, represents a
significant cognitive decline from a previous level of perfor-
mance in one or more cognitive domains—such as complex
attention, executive function, learning, memory, language or
perceptual-motor, or social cognition—which interferes
with independence in everyday activities [1,2].
Alzheimer’s disease (AD) is themost common cause of de-
mentia and accounts for 50%–70% of all diagnosed cases
[3,4]. The symptoms of AD are impairments of memory
and other cognitive skills and a gradual loss of ability to
perform activities of daily living. Similar symptoms may
occur, especially in the early course of the disease, in other
dementias, such as the behavioral variant of frontotemporal
dementia, dementia with Lewy bodies, and vascular
dementia, and in a wide range of rarer conditions, and in
atypical cases, the diagnosis may be challenging [5].
Therefore, the diagnostic criteria for AD dementia estab-
lished recently by the National Institute on Aging and the
Alzheimer’s Association [6] and the research criteria by
the International Working Group for New Research Criteria
for the Diagnosis of AD [7] recommend the use of bio-
markers, such as reduced levels of the 42-amino-acid form
of amyloid-b (Ab1–42) and elevated levels of tau and phos-
phorylated tau (p-tau) in the cerebrospinal fluid (CSF), pos-
itive amyloid positron-emission tomography (PET)
imaging, medial temporal lobe atrophy (as assessed by mag-
netic resonance imaging [MRI]), or a characteristic pattern
of glucose hypometabolism (as assessed by fluorodeoxyglu-
cose PET [FDG-PET]), when there is a need to increase the
certainty that the underlying cause of a dementia syndrome
is AD. Similar recommendations for biomarkers were pre-
sented in the most recent European Federation of Neurolog-
ical Societies guidelines for the diagnosis and management
of AD [8] and other dementias [9].
Reflecting the neuropathological hallmarks of AD, the
levels of tau, p-tau, and Ab1–42 in the CSF are easily acces-
sible biomarkers for AD [10]. However, there are no
evidence-based guidelines available to guide the applica-
tion and interpretation of CSF biomarkers in the diagnostic
evaluation of patients with dementia. The present recom-
mendations and corresponding recommendations for the
application of CSF biomarkers in patients with mild
cognitive impairment (MCI) [11], were developed by Bio-
markers for AD and Parkinson’s disease (PD; BIO-MARKAPD), which is a research program funded by the
EU Joint Program—Neurodegenerative Disease Research
(JPND), with partners from 19 countries aiming to stan-
dardize (i) biomarker measurements, (ii) sample collection,
and (iii) the interpretation of results.
The aim of this recommendation article was to provide
consensus recommendations for the clinical use of CSF
AD biomarkers in subjects with dementia, using the Grading
of Recommendations, Assessment, Development, and Eval-
uation (GRADE) method [12,13].2. Methods
2.1. Working group selection and composition
The working group for this guideline comprised 28 inter-
national members, including neurologists, psychiatrists, spe-
cialists in clinical chemistry, epidemiologists, health
economists, and researchers.
The evidence gathering, evaluation, and synthesiswere led
by five experts (SE, PJV, RH, S-KH, andAHS), and the devel-
opment of clinical recommendations was chaired by GW.
2.2. Group process
All recommendations were developed by consensus con-
ference [14]. Five face-to-face meetings were organized in
theworking group; betweenmeetings, the progress was eval-
uated by e-mail.
The face-to-face meetings were used to (i) establish a
modified GRADEmethod for the development of recommen-
dations for a diagnostic intervention; (ii) identify the most
important clinical questions and outcomes; (iii) establish the
methods for the literature search and guidelines for evaluating
the evidence; (iv) reach a consensus on each of the steps in
GRADE, including the final recommendations; and (v) reach
a consensus on additional operational aspects regarding the
implementation of CSF biomarkers in clinical practice.
The final draft of the manuscript was revised and com-
mented on by all the co-authors.
2.3. Process of preparing recommendations according to
GRADE
We used the GRADE approach for developing recommen-
dations [12,13,15]. The GRADE method provides a
systematic approach for guideline makers for first
A.H. Simonsen et al. / Alzheimer’s & Dementia 13 (2017) 274-284276formulating the correct questions to be addressed regarding a
prespecified patient population and subsequently approaching
those questions by searching for and grading the available
evidence for making final recommendations. The method was
originally developed for treatments and interventions. As our
goal was to develop recommendations for the application of a
biomarker in the diagnostic process, we modified the
GRADE approach based on recommendations reported by
Brozek et al. [13], as shown in Fig. 1.
The GRADE approach comprised eight steps (Fig. 1):Fig. 1. Modified stepwise Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) approach for the production of rec-
ommendations. PICO, population, diagnostic strategy or intervention, com-
parison strategy, and patient outcomes.2.3.1. Step 1: Formulate and rank appropriate clinical
questions for the application of GRADE
This group applied the PICO format that leads to focused
clinical questions pertaining to a predefined population (P),
diagnostic strategy or intervention (I), comparison strategy
(C), and patient outcomes (O).
2.3.2. Step 2: Identify all important clinical outcomes,
including harms, for each clinical question
The group identified and rated important clinical out-
comes and discussed related operational procedures.
2.3.3. Step 3: Identify one or more high-quality systematic
reviews and/or conduct a systematic review of the evidence
A systematic literature search to identify all the rele-
vant meta-analyses and systematic reviews was conduct-
ed. For all the clinical questions, a MEDLINE search
with predefined search strings was conducted, and more
articles were then added from other sources, including
reference lists from articles in the original search results.
Finally, a second search was conducted to identify new ar-
ticles that had been published after the first search round.
Our literature search was performed so as to achieve the
broadest coverage of published studies involving different
aspects of the diagnostic performance of CSF biomarkers
Ab1–42, total tau, and phosphorylated tau in patients with
dementia.
MEDLINE search strings are as follows:
 (Cerebrospinal fluid OR CSF) AND diagnos* AND
(Alzheimer OR AD OR dementia) AND (tau OR beta
amyloid OR abeta) AND (sensitivity OR specificity)
 (Cerebrospinal fluid OR CSF) AND diagnos* AND
(Alzheimer OR AD OR dementia) AND (tau OR beta
amyloid OR abeta) AND (MRI OR PET OR SPECT)
 (Cerebrospinal fluid OR CSF) AND diagnos* AND
(Alzheimer OR AD OR dementia) AND (tau OR
beta amyloid OR abeta).
Health economic evaluations of CSF were obtained by
updating an existing systematic review [16] for which the
search string is available on request.
Articles that included patients with several dementia
disorders were included, but articles that focused solely
on the comparison between AD and healthy aging were
excluded from this review because our aim was to provide
recommendations for differential diagnosis in patients with
dementia.
2.3.4. Step 4: Assess the quality of the studies and
summarize the evidence
After searching for evidence and identifying the relevant
clinical questions, the level of quality for each article was as-
sessed for each relevant outcome by a subset of the working
group and presented to the whole group at one of the face-to-
face meetings.
Table 1
The clinical questions and their rank of importance, based on workshop
discussion (score 1: most important, score 3: least important)
In patients with mild dementia or dementia with atypical symptoms
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grading algorithm was used as an aid. The article received
an upgraded level of quality if the patient population was
consecutively recruited from a memory clinic or consisted
of diagnostic groups typical for memory clinics, with at least
20 cases per group. The diagnostic criteria had to be well-
described, and the diagnosis had to be based on clinical
specialist consensus according to well-defined criteria and
blinded to the CSF results. If this was not the case, the level
of quality was downgraded. Detailed clinical and demo-
graphic data with clinical follow-up for at least 1 year
increased the level of quality. Furthermore, a detailed
description of the analytical method used in a single labora-
tory with reported cut-off values was seen as essential for
high quality. An autopsy-confirmed diagnosis was included
as a further criterion that increased the level of quality.
The results of grading the quality of evidence in each
research article were added to the evidence tables, and the
overall quality of evidence for each clinical question was
discussed in the face-to-face meetings and used to formulate
the final recommendations.
2.3.5. Steps 5–7: Grade the quality of the evidence for each
relevant outcome defined in Step 2 as “high,” “moderate,”
“low,” or “very low.” Consider factors that may raise the
quality of observational studies from low to moderate or
high and grade the overall quality of evidence for each
clinical question
Steps 5–7 were prepared by subgroups and approved by
the working group as a whole.
2.3.6. Step 8: Determine the direction and strength of a
recommendation
Determinants of strength of recommendations according
to GRADE are quality of evidence, balance between desir-
able and undesirable effects, values and preferences, and
costs [15]. Step 8 was carried out in the form of group discus-
sions and voting at the final face-to-face meeting.
2.4. Operational aspects
In addition, the group discussed several operational as-
pects, namely (i) the possible complications of LP and (ii)
the interpretation of laboratory results, which were judged
as important for the application of CSF biomarker investiga-
tions in clinical practice even if there was no published evi-
dence available. In these cases, recommendations were
made after focused discussions in the working group.or an ambiguous dementia subtype diagnosis, will AD CSF
biomarkers (alone or in combination) compared with (A) clinical
measures and/or (B) other imaging biomarkers. Rank
1. Identify or exclude AD as the cause of dementia? 1
2. Predict the rate of clinical decline? 2
3. Guide management? 2
4. Improve well-being? 2
5. Reduce healthcare costs? 3
Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid.3. Results
3.1. GRADE steps 1–2: PICO definition of clinical
questions
During the first workshop meeting, the working group
identified five clinical questions to be addressed using the
PICO method. The target population was defined as patientswith dementia, the diagnostic strategy was CSF AD bio-
markers (Ab1–42, tau, and p-tau), and the comparison was
either with clinical measures alone or with other (imaging)
biomarkers. The clinical questions and their rank of impor-
tance are shown in Table 1. The working group agreed unan-
imously in the ranking of the clinical questions.
The highest rank of one was given to one clinical ques-
tion: identifying or excluding AD as the cause of dementia.
The rank of two was given to predicting the rate of clinical
progression in patients with mild or atypical dementia.
The three clinical questions on changing disease manage-
ment, improving patient well-being, and reducing healthcare
costs were discussed at length during the workshop.
Although it was evident that there would be very little evi-
dence available, the working group agreed to grade them
on their relative importance. The group was divided as re-
gards the questions concerning disease management and pa-
tient well-being, as a large number voted for the highest rank
whereas a slight majority voted for a rank of two.
The working group identified possible complications of
lumbar puncture and interpretation of conflicting biomarker
results as two other important aspects to be taken into ac-
count. Recommendations on these operations aspects are
provided as an adjunct to the recommendations.3.2. GRADE steps 3–4: Evidence gathering and quality
rating
The search for systematic reviews and meta-analyses pro-
duced 12 results that are summarized in Table 2.
The search for the diagnostic value of CSF biomarkers
produced 344 articles, of which 57 fulfilled the inclusion
criteria. The search for comparisons between CSF bio-
markers and imaging biomarkers produced 913 articles, of
which 5 articles were included in the final data analyses.
The search for the added value of CSF biomarkers produced
1277 articles, of which 22 were selected for data analyses.
There were no articles that fulfilled the criteria for the health
economy subsection. A summary of the information on the
articles identified for each subsection is shown in the
Supplementary Tables 1–3.
During the initial search process, it was evident that there
was very little or no evidence available for clinical questions
Table 2
Systematic reviews and meta-analyses describing the performance of CSF AD biomarkers in the differential diagnosis of dementia
Reference First author Year Type Timespan searched Other markers CSF marker Number of studies
Diagnosis of
AD vs.
normal aging
Diagnosis of
AD vs. other
dementias Comment
[17] Olsson 2016 Systematic
review and
meta-analysis
July 1984 to
June 2014
NFL
NSE
VLP-1
HFABP
Ab1–40
Ab1–38
sAPPa
sAPPb
Albumin ratio
YKL-40/MCP-1
GFAP
Ab1–42 131 1 A CSF signature of elevated tau and p-tau,
and reduced Ab1–42 is consistently observed
in AD. The other investigated markers need
more research.
Tau 151 1
P-tau 89 1
[18] Mo 2015 Systematic
review and
meta-analysis
January 2004 to
October 2013
Ab1–42 17 1 1 Ab has a potential utility for the differential
diagnosis of AD.
[19] Liu 2014 Meta-analysis Not mentioned Tau 16 1 1 Tau levels can distinguish between AD and
VaD in the Chinese population.
[20] Rosa 2014 Systematic
review and
meta-analysis
January 1990 to
August 2013
Ab1–42 41 1 Ab can discriminate AD patients from
healthy controls with good sensitivity and
specificity.
[21] Ferreira 2014 Systematic review January 1990 to
September 2013
Ab1–42 7 Systematic reviews
or meta and 26
primary studies
1 1 CSF biomarkers fail in distinguishing AD
from other dementias.Tau
P-tau
[22] Gaugler 2013 Meta-analysis Until January 2012 FDG-PET Tau 41 (7 meta-analyses
and 34 reviews)
1 1 CSF tau and PET had comparable diagnostic
performance.
[23] Agarwal 2011 Meta-analysis 1998–2009 Ab1–42 7 1 1 The combination of high tau and low levels of
Ab might be useful in differential diagnoses
if AD. High variation between studies, more
studies are needed.
Tau 11
[24] Bloudek 2011 Systematic
review and
meta-analysis
January 1990 to
March 2010
MRI, CT,
FDG-PET, SPECT
Ab1–42 20 1 1 SPECT and p-tau performed equally and
better than the other biomarkers for the
differentiation between AD and non-AD
dementias.
Tau 30
P-tau 24
Ab1–42 and tau 12
[25] van Harten 2011 Systematic
review and
meta-analysis
Until July 2010 Tau 52 1 Tau has insufficient diagnostic accuracy. P-
tau had slightly higher accuracy.P-tau 28
[26] Mitchell 2009 Meta-analysis Until February 2009 P-tau 18 1 1 The clinical utility of p-tau for the
differentiation between AD and other
dementias was satisfactory to poor.
[27] Formichi 2006 Systematic
review
Not mentioned Ab1–42 14 1 1 Ab and tau not specific enough to distinguish
between AD and other dementias. P-tau
increases specificity for AD differential
diagnosis.
Tau 41
P-tau 12
Ab1–42 and tau
combination
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questions would be discussed using the indirect evidence
available and group discussions.
When grading the evidence, it became apparent that there
were many articles that did not fulfil the inclusion criteria,
especially in the subsection comparing the diagnostic value
of CSF biomarkers with that of imaging biomarkers, as the
data given for each modality was insufficient. Furthermore,
the articles included in the Supplementary Tables 1–3 pre-
sent their data on diagnostic accuracy in many different
forms, which made it difficult to directly compare the re-
sults. Another limitation was that the diagnoses were based
on clinical criteria, and pathological studies have shown that
about 20% of these diagnoses may be incorrect.3.3. GRADE steps 5–7: Rating the quality of evidence for
each clinical question
The Supplementary Tables 1–3 show the articles included
in the evidence for the diagnostic performance of CSF AD
biomarkers (S1), the comparison of CSF AD biomarkers
with imaging biomarkers (S2), and the added value of CSF
biomarkers over clinical measures (S3). The overall quality
of the evidencewas rated high in terms of identifying AD pa-
thology as the cause of dementia. There were 10 studies
where patients had been followed until autopsy, in addition
to 33 studies with long-term clinical follow-up of the pa-
tients. However, in terms of the direct comparison of CSF
AD biomarkers with imaging biomarkers in the diagnostic
evaluation of a mixed group of patients with dementia, there
were only a few studies available. There were three studies
comparing CSF AD biomarkers with hippocampal atrophy
on MRI, one study comparing them with medial temporal
lobe atrophy on CT, one study comparing them with FDG-
PET, and one study comparing them with
hexamethylpropyleneamine oxime-single photon emission
computerized tomography. The results of these studies
were conflicting; so, the evidence was graded as moderate
to low. We did not find any studies comparing CSF bio-
markers with amyloid PET imaging.
Furthermore, there was only little evidence regarding
whether CSF biomarkers alone or in combination with imag-
ing biomarkers could predict the rate of progression in pa-
tients with dementia because cognitive decline was not
quantified in most identified studies.3.4. GRADE Step 8: Recommendations
The final recommendations for each clinical question and
the strength of each recommendation, which reflects the
strength of the scientific evidence, are shown in Table 3.
The working group recommended the use of CSF AD bio-
markers in patients with dementia to identify or exclude
AD as the underlying cause of dementia. Based on the evi-
dence, the recommendation was strong for patients with
mild dementia but weak for patients with atypical or
Table 3
Final recommendations and recommendation strengths
Clinical question
a) Relative to clinical measures b) Relative to other biomarkers
Answer Strength of recommendation Answer Strength of recommendation
. identify or exclude
AD as the cause of dementia?
Yes In mild dementia: strong
In atypical or ambiguous
dementia: weak
No In mild dementia: weak
In atypical or ambiguous dementia:
weak (no evidence)
. predict rate of clinical decline? Yes Weak No Weak (no evidence)
. guide management? Yes, in
ambiguous cases
Weak (no evidence) No Weak (no evidence)
. improve well-being? No Weak (no evidence) No Weak (no evidence)
. reduce healthcare costs? No Weak (no evidence) No Weak (no evidence)
Abbreviation: AD, Alzheimer’s disease.
NOTE. In patients with mild dementia or dementia with atypical symptoms or an ambiguous dementia subtype diagnosis, will cerebrospinal fluid biomarkers
(alone or in combination) as compared with (A) clinical measures and/or (B) other biomarkers..
A.H. Simonsen et al. / Alzheimer’s & Dementia 13 (2017) 274-284280ambiguous dementia. Theworking group also recommended
the use of CSF AD biomarkers to predict the future rate of
clinical decline, but because of the lower amount of quality
evidence, the strength of the recommendation was weak. In
ambiguous cases of dementia, the working group recom-
mended using CSFAD biomarkers to guide disease manage-
ment, although the strength of this recommendation was
weak because of the lack of evidence. The working group
did not find sufficient evidence to recommend the use of
CSF AD biomarkers to improve the patient’s well-being or
to reduce healthcare costs.
As the evidence regarding the comparison of CSF AD
biomarkers with imaging biomarkers was conflicting, the
working group could not recommend CSF biomarkers above
any imaging biomarker.3.5. Operational aspects of the application of CSF
biomarkers in patients with dementia3.5.1. Role of CSF biomarkers in the diagnostic evaluation
of patients
Patients with dementia should be offered a thorough diag-
nostic evaluation to identify possible causes that require spe-
cific treatment and follow-up. This evaluation would at least
include obtaining medical and family history from an infor-
mant, a psychiatric evaluation, a physical (including neuro-
logical) examination, neuropsychological testing, a cranial
CT or MRI, and laboratory screening tests [8]. Adding
CSF or another AD biomarker study to the primary diag-
nostic evaluation will help identify patients with dementia
because of AD and thereby patients who may potentially
benefit from cholinesterase inhibitors and memantine. This
may also serve as a way to exclude AD in atypical cases.
The available evidence does not support the choice of one
biomarker above another. Thus, the choice of biomarker
may depend on cost, availability, and other indications for
performing the biomarker study (e.g., lumbar puncture in pa-
tients with possible inflammatory disease).3.5.2. Interpretation of CSF biomarker results in patients
who meet general dementia criteria
In cases where CSF biomarker results indicate demen-
tia because of AD: in patients where the CSF levels of
Ab1–42 are decreased and the levels of tau and phospho-
tau are increased in relation to predefined cut-points, there
is a greater probability that dementia is caused by AD. In
such cases, the patient should be offered treatment with
cholinesterase inhibitors or memantine and nonpharmaco-
logical treatment and counseling. Also, patients with de-
mentia because of AD may be offered the possibility to
participate in clinical trials with new, potentially disease-
modifying drugs that target the neuropathological hall-
marks of AD, of which the biomarkers are in vivo
correlates.
In cases where the levels of CSF Ab1–42, tau, and p-tau
levels are conflicting: in patients with reduced CSF Ab1–42,
but normal tau and/or p-tau levels, AD as the cause of de-
mentia is still a possibility, although less likely. In these
cases, it is recommended that the CSF cell count and albu-
min quotient and the cut-offs for CSF Ab1–42 are checked.
A CSF reanalysis may be considered and another (imaging)
biomarker may be added to clarify the diagnosis. In patients
with elevated tau or p-tau, but normal Ab1–42, other neurode-
generative disorders may be considered and other bio-
markers such as Ab1–40 or imaging biomarkers may be
added to clarify the diagnosis [29,30].
In cases where the levels of CSF Ab1–42, tau, and
phospho-tau are normal: it is unlikely that AD is the cause
of dementia. Other biomarker modalities may be used to
clarify the diagnosis.
In cases where the levels of CSF Ab1–42, tau, and
phospho-tau are close to the cut-off points: results close
to the cut-off points should be interpreted with care. An
inherent analytical variability of 10% for the used assays
results in a gray zone with uncertain biomarker values
[31]. In these cases, another (imaging) biomarker may
be added to clarify the diagnosis or the analysis may
be repeated.
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The possible contraindications (increased intracranial
pressure, coagulopathy, and a skin infection at the injection
site) must be assessed thoroughly. For example, the current
use of anticoagulants is a contraindication for LP, and the
risk of cessation of anticoagulants for LP because of an
AD biomarker test must be carefully considered. Of all the
patients included in a multicenter LP feasibility study
(n 5 3868), 17% reported back pain, 19% reported head-
ache, and 9% reported typical post-LP headache. An atrau-
matic needle and an age of .65 years were preventive
[32]. When LP is performed correctly, in compliance with
the consensus recommendations for the LP procedure, it is
generally well tolerated and accepted with a low complica-
tion rate. Hence, in patients with dementia, although
possible contraindications should be considered carefully
in the individual patient, the value of a lumbar puncture
for diagnostic purposes usually exceeds the risk of complica-
tions from the procedure.
3.5.4. Costs and availability
CSF biomarker cost estimates range from V130–622
[33–35]. The estimates are lower than related biomarkers
in FDG-PET ($1671 [1999] [36], $1661 [assumed in 2001]
[37], V507 [assumed in 2004] [38]). A routine clinical
CSF biomarker test is readily available, and the samples
can be sent for analyses elsewhere. However, LP requires
personnel with the appropriate training and facilities. The
introduction of lumbar punctures into the routine clinical
diagnostic workup would therefore raise logistical issues
of upscaling that must be addressed [39].
One study researched the cost-effectiveness of CSF bio-
markers [40]. Several aspects limited the generalizability
of the study. The use of the intermediate outcome of addi-
tional costs per additional correct diagnosis in combination
with the unknownmaximumwillingness to pay for one addi-
tional correct diagnosis limits the advising of adopting the
CSF test in clinical practice from a societal perspective.
Furthermore, the CSF test was simulated as a replacement
test in the current diagnostic workup. Therefore, the results
of this study are not considered as evidence for cost-
effectiveness in terms of dementia in a clinical setting.
Because of a lack of evidence, the group could not recom-
mend the use of CSF biomarkers to reduce healthcare costs.4. Discussion
This article presents the outcomes of an expert working
group, established under the JPND BIOMARKAPD pro-
gram, which aimed to produce recommendations for the
clinical application of CSF biomarkers in the differential
diagnosis of patients with dementia. By applying the
GRADE method and a systematic literature search, a
consensus was reached on the recommendations for several
aspects of the clinical application of CSF biomarkers in this
group of patients.An accurate and early diagnosis is important to be able to
differentiate patients with AD from patients suffering from
dementia because of other causes and to ensure appropriate
pharmacological treatment, counseling, and inclusion in
clinical trials.
The application of CSF AD biomarkers in the clinical
routine has been hampered by a lack of harmonization and
standardization. There is also uncertainty about the role of
CSF in relation to other biomarkers. The use of biomarkers
in patients with subjective cognitive complaints or MCI to
predict future dementia or diagnose AD at a very early stage
is associated with a range of unique ethical and logistical
challenges that are discussed in a separate article [11]. For
patients who have already developed dementia and are
referred to diagnostic evaluation, the differential diagnosis
of AD versus other dementia disorders may be challenging,
particularly in atypical and uncertain cases.
Hence, the most important clinical question was defined
by the GRADE working group as “in patients with mild de-
mentia or dementia with atypical symptoms or an ambiguous
dementia subtype diagnosis, will CSF biomarkers for AD
compared with clinical measures alone or other (imaging)
AD biomarkers identify or exclude AD as the cause of de-
mentia?”
We found sufficient evidence to support the use CSF
biomarkers alongside clinical measures to identify or
exclude AD as the underlying cause of dementia. In terms
of comparing the diagnostic performance of CSF bio-
markers to other AD biomarkers, medial temporal lobe at-
rophy on MRI, FDG-PET, or amyloid PET, there were
only a few articles on the topic, and the results were con-
flicting as to the superiority of CSF AD biomarkers. Thus,
the working group did not find sufficient evidence to sup-
port a recommendation of CSF biomarkers above any
other (imaging) biomarker for to identify or exclude AD
as the cause of dementia.
Furthermore, we did not find any published studies on
the potential effect of CSF biomarkers on disease manage-
ment, improving the quality of life or healthcare costs.
Hence, these questions were indirectly assessed in light
of the available literature and group discussions. The
working group recommended the application of AD CSF
biomarkers to guide disease management in ambiguous
dementia cases. However, the group did not find evidence
to support any recommendation of using AD CSF bio-
markers to improve patient well-being or reduce health-
care costs.
Many of the studies found in our literature search
described the diagnostic accuracy of CSF biomarkers in
the differentiation between AD and healthy ageing, and
only a few studies addressed the differentiation between
AD and other dementia diseases. For clinicians managing
patients with dementia, differentiation between healthy ag-
ing and AD is not highly relevant, whereas it is important
to obtain a reliable differential diagnosis between different
diseases causing dementia.
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was presented separately from the value of analyzing other
CSF measures with potential diagnostic importance. The
analysis of CSF for AD biomarkers is an easily accessible
test, particularly in terms of patients for whom lumbar punc-
ture with routine CSF analysis is already indicated. Thus,
CSF analyses may serve several diagnostic purposes at the
same time, for example, investigation of the blood-brain bar-
rier integrity, presence of neuroinflammation, or infection
and elucidation of whether AD is the cause of dementia.
The strength of our set of recommendations was devel-
oped using a systematic approach, the GRADE method,
and by an international, multidisciplinary team with long-
term clinical and research experience and based on the re-
view and evaluation of a vast amount of research evidence
and five face-to-face consensus meetings. The GRADE
method was originally developed for therapeutic interven-
tions, and the translation to diagnostic interventions is com-
plex, particularly in a field, as the present, with significant
gaps in evidence. Even with the application of a systematic
approach, it is a potential limitation that the outcome of the
consensus method is sensitive to the composition of the
group and to group dynamics.
Our literature search emphasized a need for more studies
that compare the value of CSF and imaging biomarkers in
the differential diagnosis of patients with dementia and to
fill the gap ofmissing evidence on the important clinical ques-
tion of improving patient well-being (clinical validity and
utility). More evidence would help inform clinicians about
the choice of biomarkers, which should be based on evidence
and on potential contraindications, availability, and cost.
In conclusion, using a GRADE-based approach based on
currently available evidence, the BIOMARKAPD working
group recommended the use of CSF AD biomarkers in the
diagnostic evaluation of patients with dementia as a supple-
ment to clinical evaluation, particularly in uncertain and
atypical cases, to identify or exclude AD as the underlying
cause, after having ranked this clinical question as the
most important. The working group also recommended the
use of CSF biomarkers to predict the rate of clinical decline.
CSF AD biomarkers are readily accessible and may help to
identify or exclude AD as the cause of dementia with impor-
tant implications for treatment. However, no recommenda-
tions could be given on the choice of CSF biomarkers
versus other potential AD biomarkers because of insufficient
or conflicting evidence.Acknowledgments
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1. Systematic review: The authors developed recom-
mendations for use of CSF AD biomarkers in diag-
nostic evaluation of dementia, using the Grading of
Recommendations Assessment, Development, and
Evaluation (GRADE) method based on systematic
review of the literature and structured group discus-
sions. Despite numerous clinical studies on CSF
AD biomarkers, there were no evidence-based rec-
ommendations available to guide the application
and interpretation of CSF biomarkers in the evalua-
tion of patients with dementia.
2. Interpretation: The group recommends the use of
CSFAD biomarkers as a supplement to clinical eval-
uation, to identify or exclude AD as the cause of de-
mentia, for prognostic evaluation, and for guiding
management of patients, particularly in atypical
and uncertain cases.
3. Future directions: Studies comparing the diagnostic
value of CSF and imaging biomarkers for AD are
needed, as well as studies assessing whether the
application of biomarkers in diagnostic evaluation
can improve patient well-being as a final outcome.References
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